Steward Partners Investment Advisory, LLC
Position in DNLI — Denali Therapeutics Inc.
CIK 1723397
STAMFORD, CT
Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$8,744
+$6,133 QoQ
Shares Held
340
+150.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#236
of 290 holders
Holding Since
Dec 2024
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Steward Partners Investment Advisory, LLC holds $58,578,486 across 161 Biotechnology names. DNLI ranks #92 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VKTX |
Viking Therapeutics, Inc.
|
351,178 | $13,699,453 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
20,851 | $10,357,317 | |
| 3 | ARGX |
Argenx SE
|
9,982 | $9,261,000 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,148 | $3,209,983 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
55,012 | $3,147,786 | |
| 6 | CRMD |
CorMedix Inc.
|
232,615 | $1,826,027 | |
| 7 | OCUL |
Ocular Therapeutix, Inc
|
165,142 | $1,621,694 | |
| 8 | NKTR |
Nektar Therapeutics
|
18,279 | $1,276,056 |
All Filings in DNLI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,744 | 340 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $2,611 | 136 | Shares | Sole | 2026-05-08 | |
| 2025-03-31 | $339 | 25 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $509 | 25 | Shares | Sole | 2025-02-06 | |
| No filing history on record for this holder in this stock. | ||||||